Postrelease Risk of Overdose and All-Cause Death Among Persons Released From Jail or Prison: Minnesota, March 2020-December 2021.
Hill K, Bodurtha P, Winkelman T, Howell B. Postrelease Risk of Overdose and All-Cause Death Among Persons Released From Jail or Prison: Minnesota, March 2020-December 2021. American Journal Of Public Health 2024, 114: 913-922. PMID: 39024534, PMCID: PMC11306622, DOI: 10.2105/ajph.2024.307723.Peer-Reviewed Original ResearchConceptsOverdose deathsPrison exposureJailPrisonRisk of overdoseRates of overdose deathsOverdose death ratesOpioid use disorderGeneral populationDeath recordsDrug overdosePeopleStandardized mortality ratioPersonsIncarcerationUse disorderPostreleaseMortality ratioDeath rateRisk of deathRetrospective cohort studyMortality riskCohort studyMinnesotaOverdoseBuprenorphine-naloxone vs. extended-release naltrexone for opioid use disorder in individuals with and without criminal legal involvement: A secondary analysis of the X:BOT randomized controlled trial
Balter D, Puglisi L, Dziura J, Fiellin D, Howell B. Buprenorphine-naloxone vs. extended-release naltrexone for opioid use disorder in individuals with and without criminal legal involvement: A secondary analysis of the X:BOT randomized controlled trial. Journal Of Substance Use And Addiction Treatment 2024, 164: 209438. PMID: 38857827, PMCID: PMC11300157, DOI: 10.1016/j.josat.2024.209438.Peer-Reviewed Original ResearchXR-NTXBuprenorphine-naloxoneOpioid use disorderCriminal legal involvementUse disorderHazard of overdoseLifetime incarcerationLegal involvementOpioid use disorder treatment outcomesPer-protocol analysisExtended-release naltrexoneMOUD effectivenessTreatment outcomesEffects of medicationHazard of relapseSecondary analysisIntention-to-treat analysisIntention-to-treatRandomized controlled trialsEffects of MOUDRelapseControlled trialsDisordersOpioidPotential effect modifiers